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Abstract
Bisphosphonates (BPs) are the first line treatment for many bone diseases including hypercalcimia associated with bone malignancies. In this paper, we introduce a 
new analogue of bisphosphonate called the 2,3,3-Trisphosphonate (2,3,3-TriPP) that was synthesised in a two steps reaction. In vitro investigations using a medically 
known bisphosphonate (Etidronate) and the 2,3,3-TrisPP were performed with an aim to evaluate biological effect of this novel compound in major bone cells. 
2,3,3-TrisPP showed to have potential to supress the bone resorption process, as our data found that this novel compound exhibited cytotoxic effect in osteoclastic 
cells at a low concentration of 0.172 mg/mL (LC50). A molecular docking computational simulation calculated a high level of binding affinity between the human 
farnesyl pyrophosphate synthase (hFPPS) and 2,3,3-TrisPP. This calculation suggested 2,3,3TrisPP may have undergone the mevalonate pathway to prevent the 
prenylation step during biosynthesis and subsequently resulted in the deactivation of osteoclastic cells. Finally, high levels of osteoblast mineralisation potentials were 
recorded upon treatments with 2,3,3-TrisPP (0.01-0.1 mg/ml), which implied 2,3,3-TrsiPP may also facilitate bone regeneration.
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Introduction 
Bisphosphonate (BP) [1] is an important class of anti-resorptive 
medications for osteoporosis, [2] Paget’s diseases, [3] hypercalcimia 
associated with bone metastasis [4-8] and other disorders involving 
excessive bone loss [9]. There are two classes of BP, the nitrogen-
containing bisphosphonates (N-BP) and the non-nitrogen containing 
bisphosphonates (BP). These BP analogues exhibit excellent bio-
distributions on bone surface (hydroxyapatite) by chelating Calcium 
ions. Although the non-nitrogen BPs undergo cellular reaction 
to manipulate the ATP biosynthesis (Figure 1), while the N-BPs 
selectively bind to farnesylpyrophosphate synthase (FPPS) to inhibit 
the mevalonate pathway (Figure 2), both mechanisms eventually lead to 
suppression of the bone resorption process via inhibition of osteoclast 
activities [10-12]. Due to the selective inhibitory ability of N-BPs on 
the isoprenoid and cholesterol biosynthesis, extensive studies of BPs 
have been carried out to unveil their potential applications to other 
diseases related to Alzheimer’s, immunomodulator and parasitological 
infections [13-16]. BPs are also known to own special metal-binding 
properties, [17] which has made great interests to scientists to explore 
the chemistry and metal conjugations of this category of compounds, 
[18,19] in particular for the development in nuclear medicines (186Re 
therapy) [20] and radiopharmaceuticals (99Tc imaging), [21-23] in 
advance material discoveries for bone and dental implants [24-26] as 
well as in nanotechnologies [27-29]. 
Evidence from preclinical models have shown that N-BPs are 
generally up to several orders of magnitude more potent than the 
conventional BPs at inhibiting bone resorption. However, the 
disadvantage of administering N-BPs is that patients are at risk of 
developing severe N-bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) [30] and gastric inflammation [31-33]. Considering these 
adverse effects, nonnitrogen containing BPs (i.e. Clodronate) are 
still widely prescribed, especially to cancer patients who are in poor 
physical states [34,35].
There are over twenty clinically approved BPs on the market, many 
other derivatives have been synthesised, studied and reported [36-
38]. Griffiths, et al. have recently published a convenient method to 
synthesise a range of novel 2,3,3-trisphosphonates 2 (Figure 3), a new 
class of the non-nitrogen containing geminal BPs [39]. The synthesis 
of these 2,3,3-trisphosphonate derivatives 2 (R=Me, Et or iPr) involve 
‘one-pot reactions’ using 3,4-dihalogenated maleic anhydride and 
Figure 1. Chemical structures of ATP and its manipulated version after pyrophosphate 
group is replaced by a bisphosphonate group (e.g. Etidronate). 
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to stir under a sealed condition at room temperature for a further 16 
hours. This crude ylidic bisphosphonate 1 was then purified by silica 
gel chromatography using a gradient solvent of dichloromethane 
and acetonitrile mixtures as eluent. Chromatography fractions were 
analysed using silica based tlc plate, which was developed using 100 % 
acetonitrile as mobile phase solvent system and then visualised under 
UV light to determine present of ylidic bisphosphonate 1 collected. 
Volatile components of the collected chromatography fractions were 
removed under reduced pressure (55°C at 10 mmHg), NMR spectra 
of the obtained green oil confirmed ylidic bisphosphonate was formed 
in a high state of purity [39]. A stream of dry Hydrogen Chloride 
gas was bubbled into this freshly prepared ylidic bisphosphonate 
1 in dichloromethane (20 mL) over a period of 20 minutes, this 
homogeneous solution was stirred for a further 1 hour before volatile 
components were removed under reduced pressure (35°C at 10 
mmHg). The residue was then re-dissolved into 20 mL of aqueous 
acetonitrile (1:1 ratio) and stirred at room temperature overnight. 
Crude 2,3,3-TrisPP was obtained as pale-yellow oil after removal 
of volatile components in vacuo. This sample was firstly isolated via 
solvent extraction using dichloromethane and water mixtures. Water 
layers were collected and combined, volatile components were then 
removed in vacuo (45°C at 0.01 mmHg), residue was subsequently 
washed and triturated from initially DCM and then ethyl acetate multiple 
times. A pure sample of 2,3,3-TrisPP (0.8 g, 45 %) was finally obtained 
as colourless solid after removing excess water under reduced pressure. 
Original method and analytic data of 2,3,3-TrisPP had been previously 
reported by Griffiths, et al. 
NMR characterisation of 2,3,3-TrisPP 
NMR spectra were recorded on a JEOL EX-600 spectrometer 
located at the Department of Pharmacy, University of Hertfordshire. 
Chemical shifts are reported in ‘ppm’ whereas coupling constants 
(J values) are measured in Hertz. Etidronate (Etidronic acid) was 
purchased from Sigma-Aldrich, while 2,3,3-TrisPP as prepared 
in situ, both samples were dissolved in D2O (Goss Scientific Ltd.) 
and all NMR experiments performed using 5 mm diameter NMR 
glass tubes. Hydrogen resonances (δH 5.30 ppm) present in residual 
water in samples were irradiated and suppressed during all 1H NMR 
acquisitions. NMR data set were recorded using Dalta and the resulting 
spectra were processed using MestRe Nova. NMR spectra of Etidronate 
and 2,3,3-TrisPP can be found in supplementary files provided. † 31P 
three equivalents of trialkylphosphite at ambient temperature. These 
reactions give initially ylidic bisphosphonates 1 (R = Me, Et or iPr) as 
stable intermediates, which subsequently undergo protonation to give 
the ring opened trisphosphonic esters 2 (R=Me, Et or iPr). A complete 
hydrolysis of the trisphosphosphic ester 2 (R = Et) under acid condition 
gives the desired 2,3,3-TrisPP (Figure 4), the compound that was used 
in this biological report. 
The first biological study of the 2,3,3-TrisPP reported by Yang, et 
al. who has revealed the intercellular Ca2+ binding ability of this novel 
system in a neurocellular research. 2,3,3-TrisPP was found to chelate 
with Ca2+ ions intercellularly, which had led to neuro-protective 
effects in PC12 cells via mechanisms involving Ca2+ attenuation and 
oxidative stress relief [40]. With regard to the chemical structure 
relationship, 2,3,3-TrisPP shares a common feature to all typical BPs 
(i.e. Etidronate), it contains a geminal bisphosphonate unit (PC-
P) where the two phosphonic acid groups share the same α-carbon 
atom [41]. Besides, this novel 2,3,3TrisPP owns an extra phosphoryl 
unit, locates in very close proximity to the germinal BP moiety. The 
present of this additional phosphoryl unit is expected to enhance 
functionalities, pharmacokinetic and antiresorptive effects in bones, as 
well as to ameliorate adverse effects and complications cause by current 
NBP treatments. 
Materials and methods 
Chemicals and reagents 
Organic solvents such as dichloromethane, acetone, acetonitrile, 
ethyl acetate etc, were purchased from VWR. TLC was performed with 
alumina backed silica gel 60 F254 eluting with the solvent system used 
for the column chromatography and the plates were visualised under 
UV light or developed in an iodine tank. Column chromatography 
used silica gel with particle size 33–50 µm and was purchased from 
BDH. All other materials including dichloromaleic anhydride and 
triethylphosphite were purchased from Sigma-Aldrich. All other 
chemicals were used as received unless otherwise indicated. 
Preparation of 2,3,3-TrisPP in situ 
Triethylphosphite (2.98 g, 18mmol) in a syringe was added 
dropwise into a stirred solution of dichloromaleic anhydride (1 g, 5.9 
mmol) and dried dichloromethane (15 mL) through a lose septum over 
a period of 15 minutes. The resulting reaction mixture was then allowed 
 
Figure 2. The Mevalonate pathway: FPPS is required to catalyse the twostep synthesis of farnesyl pyrophosphate (FPP) and garanyl diphosphate (GPP) for osteoclast function and viability. 
 
Figure 3. Synthetic approach for trisphosphonic ester 2 (precursor of 2,3,3-TrisPP). Figure 4. Chemical structures of 2,3,3-TrisPP and Etidronate (a clinical BP). 
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NMR of 2,3,3-TrisPP (243 MHz; D2O) δ 17.09 (br s, P-C), 18.50 (2 P, br 
s, P-C-P); 13C NMR of 2,3,3-TrisPP (150.9 MHz, D2O) δ 37.4 (t, JPC 123 
Hz, P-C-P), 43.7 (dt, JPC 118 & 18 Hz, P-C), 170.9 (CO2H). 1H NMR of 
2,3,3-TrisPP (400 MHz, D2O) δ 2.35 (1 H, tdd, JPH 24 & 12 Hz, JHH 3 Hz, 
P2CH), δ 2.90 (1H, m, PCH). 
Osteoclast in vitro assay 
Cell culture 
RAW 264.7 cells (purchased from ATCC), are mouse leukaemic 
monocyte–macrophage cell line. It was incubated in a minimal essential 
medium (Gibco) with 10 vol.% fetal calf serum (FCS), which was then 
stimulated using macrophage colony-stimulating factor (M-CSF, 5 ng/
ml, Biochrom) and receptor activator of the NFƘB ligand (RANKL, 40 
ng/ml, Biochrom) for 14 day. These factors induced the differentiation 
of the monocytes-macrophages into osteoclast-like cells.† In vitro 
experiments were then carried out by treating these osteoclast-like 
cells using different concentrations of Etidronates or 2,3,3TrisPP for 24 
hours prior assessments. Identification of Osteoclatic cells 
Cell morphology of the affected cells was studied by light 
microscope (Axiovert, Zeiss, Germany). Investigations of Tartrate-
resistant acid phosphatase (TRAP) activities of RAW 264.7 cells were 
performed using TRAP ELF 97 (Molecular Probes®) whereas the cells 
were stained with Phalloidin and DAPI (Molecular Probes®) and 
observed under fluorescence microscope (AxioVert Zeiss, Germany) 
to investigate the actin ring expression. 
Cell viability 
WST-8 assay (Sigma-Aldrich), a CCk-8 cell counting kit was used 
to assess the viability of the cultivated cells. 
Osteoclast-like cells were treated with different concentrations 
(0.01-2 mg/mL) of Etidronate and 2,3,3TrisPP for 24 hours. Culture 
media was removed from the cell culture wells plates and the cells were 
washed twice with PBS. After addition of CCK-8 solution in each well, 
the plates were incubated for 1 hour to allow conversion of tetrazolium 
to an orange formazan product by mitochondrial enzymes (cellular 
dehydrogenases). Finally, the solution was seeded in a 96-well plate, 
mitochondrial activities were measured by colorimetric assay using a 
spectrophotometer (Phomo, Anthos Mikrosysteme GmbH, Germany). 
The intensities of absorbance (λabs 450 nm) of the affected osteoclast-
like cells were measured, the mitochondrial activities and the number 
of viable cells in the cytotoxic assay were also calculated. 
Quantification analysis 
For statistical analysis of the differences of the mitochondrial 
activity, the one-way analysis of variance (ANOVA) was used, which 
is implemented in Origin 9G software (OriginLab Corporations, USA). 
The number of samples was N=6 for the mitochondrial activity and for 
the morphological studies. The significance level was set as p < 0.05 = *, 
p< 0.01 = ** and p < 0.001 = ***. For the comparison of the mean values the 
Tukey test was used. LC50 value (lethal concentration of the used solution 
where the activity of the cells is reduced to 50 %) was calculated. 
Molecular protein-ligand docking simulation 
Docking calculations were carried out using DockingServer [42]. 
Gasteiger partial charges were added to the ligand atoms. Non-polar 
hydrogen atoms were merged, and rotatable bonds were defined. 
Docking calculations were carried out on TrisPP-hFPPS model, where 
2,3,3-TrisPP ligand was generated by ChemBioDraw ultra 13.0 and 
the macromolecule of human FPPS was downloaded from the RCSB 
Protein Data Bank as an un-liganded protein (2F7M) [41]. Essential 
hydrogen atoms, Kollman united atom type charges, and solvation 
parameters were added with the aid of AutoDock tools [43]. Affinity 
(grid) maps of 40x25x30 Å grid points and 0.375 Å spacing were 
generated using the Autogrid program. AutoDock parameter set- and 
distance-dependent dielectric functions were used in the calculation of 
the van der Waals and the electrostatic terms, respectively. Docking 
simulations were performed using the Lamarckian genetic algorithm 
(LGA) and the Solis & Wets local search method [44]. Initial position, 
orientation, and torsions of the 2,3,3-TrisPP molecules were set 
randomly. All rotatable torsions were released during docking. Each 
docking experiment was derived from 100 different runs that were 
set to terminate after a maximum of 2500000 energy evaluations. The 
population size was set to 150. During the search, a translational step of 
0.2 Å, quaternion and torsion steps of 5 were applied.  
Osteoblast in vitro assay 
Cell culture: MC3T3-E1 cells (purchased from ATCC) were 
cultured in a-MEM (Lonza, Switzerland) supplemented with 10% fetal 
bovine serum (FBS) and antibiotics (10U/L penicillin and 100mg/L 
streptomycin) in a humidified atmosphere containing 10% CO2 at 37°C 
and the medium changed every two days. Cells were seeded in 96-wells 
plates (1000 cells/well) for proliferation assay and ALP activity assay. 
Cell proliferation assay 
Total DNA content was measured to quantify the cellular 
proliferation as previously described [45]. Briefly, the cells were 
collected 1, 4, 7, and 10 days after 2,3,3-TrisPP (0, 0.01, 0.1 and 0.5 
mg/ml) treatment and stored at -20oC. With all time points collected, 
cells were thawed at room temperature and 100μl distilled water was 
added to each well then refrozen. After 24 hrs thawed again and 100μl 
of the fluorochrome Hoechst 33258 at the concentration 20μg/ml in 
high salt TNE buffer (2M NaCl) was added to each well. The plates were 
read with excitation at λ 350nm and emission at λ 460nm. Cell number 
was calculated according to the cell number standard curve. The results 
were collected from three independent experiments. 
Differentiation assay  
To determine the early 2,3,3-TrisPP induced differentiation of 
MC3T3-E1 cells, ALP activity was assessed. Sample collection and 
preparation was the same as cell proliferation assay. After that 100μl 
ALP reaction solution (20mg 4-Nitropheyl-phosphate disodium salt 
hexahydrate tablet was dissolved in 8ml 2,3,3-TrisPP buffer solution 
(pH=9.5) containing 15μl of 2M MgCl2) was added to cell lysate, 
incubated in 37oC for 1 hr., then pNP formation was measured at 405 
nm with a spectrophotometer. ALP activity was calculated according to 
the standard curve and normalised by cell number. Experiments were 
performed three times. 
Mineralisation 
For Alizarin Red S staining, 24-wells plates were used with 5×103 
cells/well cultured. Cells were treated with osteogenic differentiation 
medium (OM, containing 10% FBS, 50μg/ml L-ascorbic acid, 5mM 
βglycerophosphate and 10nM dexamethasone) for mineralisation 
study. After 3, 4 and 5 weeks, the cells were washed with PBS and fixed 
in 4% glutaraldehyde for 30min, then stained with 2% Alizarin Red S 
(Sigma-Aldrich, St Louis, MO, USA) for 1 hr at room temperature, 
after that they were washed three times with distilled water to 
remove unbound stain, and air-dried before being photographed. For 
quantification, stain was extracted with 10% cetylpyridinum chloride in 
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deionized water, and then incubated for 1 hr. at the room temperature, 
and then the absorbance of the supernatant was measured at 560 nm. 
The data were collected from three same conditioned wells. 
Results 
General 
2,3,3-TrisPP as shown in figure 4 was synthesised and isolated in 
situ using a modification procedure of Griffith, et al. (Figure 3) [39]. 
A more established purification method is indeed reported herein, the 
chemical structure and purity of the 2,3,3-TrisPP was assessed by 31P, 
13C and 1H NMR spectroscopes. † Synthetic 2,3,3-TrisPP was dissolved 
in purified water prior all biological testing.† With an aim to examine 
biological activities of 2,3,3-TrisPP in major bone cells, differentiated 
osteoclastic (RAW264.7) [46,47] and preosteoblastic (MC3T3-E1) 
[48] cell-lines were employed in our in vitro studies. Parallel studies 
using commercially available Etidronate were performed to enable 
comparison in their biological effects [49] and standard evaluations of 
novel 2,3,3-TrisPP. 
In vitro osteoclast assay 
TRAP and Actin Ring expression 
Cytotoxic effects in osteoclastic cells induced by different 
concentrations (0.01 – 2 mg/ml) of Etidronate and 2,3,3-TrisPP were 
initially assessed by microscopic imaging. † Selective images from 
cell morphology studies showed cell fragments of the differentiated 
RAW264.7 culture after it was exposed to 0.5 mg/ml of Etidronate 
(Figure 5a) and 2,3,3-TrisPP (Figure 5b) for 24 hours. A remarkable 
decrease in number of cells was observed when cells were exposed to 
2,3,3-TrisPP (Figure 5b). To study the cell behaviour of these affected 
cultures, actin ring characterisation was carried out using Phalloidin/
DAPI staining protocol. (Figure 5c) (0.5 mg/ml Etidronate) and (Figure 
5d) (0.5 mg/ml 2,3,3-TrisPP) showed selective fluorescent images† 
of nuclei counterstained with DAPI (blue) while actin filaments 
were stained with Phalloidin (red). To identify TRAP activities in 
the affected osteoclastic cells, a histochemical staining method was 
performed using fluorescent-based ELF97 substrates. (Figure 5e) and 
(figure 5f) showed selective fluorescent images† of TRAP expression 
after osteoclastic cells were exposed to 0.5 mg/ml of Etidronate and 
2,3,3-TrisPP respectively. An obvious cytotoxic effect was observed 
from both TRAP and actin ring studies after osteoclast-like cells 
were incubated in 0.5 mg/ml of 2,3,3-TrisPP at 37°C for 24 hours. In 
contrast, almost 2 mg/ml of Etidronate was required to exhibit a level 
of toxic effect in the osteoclast-like cell cultures. † 
Cell viabilities and LC50 
Cell viability of the osteoclastic cells were assessed by WST-8 
assay to determine the lethal concentrations (LC50) required from 
Etidronate and 2,3,3-TrisPP to reduce the cell viability by half. A 
trend of decreasing in cell numbers was observed (Figure 6a) when 
osteoclastic cultures were treated with Etidronate and 2,3,3TrisPP 
at various concentrations (0.01-2 mg/ml) for 24 hours. Figure 6b 
indicates normalised results of cell vitality (%), while 0.01-0.1 mg/ml 
of Etidronate did not induce any cytotoxic effect on the osteoclast-like 
cells, 2,3,3-TrisPP treatments showed immediate cell necrosis by 6.3 
and 30 % at the same concentrations. As 0.5-1 mg/ml of Etidronate 
treatments began to show a reduction in cell numbers by 15-40%, 
2,3,3-TrisPP efficiently suppressed osteoclastic mitochondrial activities 
by over 90% at the same concentration. Finally, the rates of cell 
viability were measured and the corresponding LC50 for Etidronate and 
2,3,3-TrisPP in osteoclastic cells were subsequently calculated as 1.25 
and 0.172 mg/ml respectively (Figure 6b). 
Figure 5. Light microscope images of cell morphology studies after osteoclast-like cells were exposed to 0.5 mg/ml of (a) Etidronate and (b) TrisPP. Fluorescent images of Actin ring 
staining of the same culture at 0.5mg/ml of (c) Etidronate and (d) TrisPP. TRAP staining images of the same culture with the 0.5mg/ml of Etidronate (e) and TrisPP (f). 
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Molecular ligand-protein docking simulation 
DockingSever (a web-based computer program) was used to 
perform ligand-protein docking simulation of the 2,3,3-TrisPP and 
human farnesyl pyrophosphate synthase (hFPPS) model. Among 100 
docking results, the first set was selected as the most stable and adapted 
docking position, this is determined by the lowest binding energies 
collected from an independent calculation. As illustrated in Table 1, 
low and negative binding forces (kcal/mol) were obtained to achieve 
maximum interactions between the single 2,3,3-TrisPP ligand and 
amino acid units within the hFPPS protein (Figure 7a). Figure 7a also 
displayed the three major hydrogen bond formations via the O--H—N 
and O—H--O interactions involving two phosphoryl and a carboxylate 
unit in the 2,3,3-TrisPP ligand with the amide and carbonyl unit in the 
hFPPS protein. Moreover, calculations obtained from this simulation 
indicated further potential satisfying hydrogen bonding formations 
of the 2,3,3-TrisPP-hFPPS model (Figure 7b) can be achieved at amino 
acid sequence 174 (ASP), 193 (TYR), 196 (ILE), 197 (VAL), 200 (LYS), 
201 (THR), 240 (GLN), 243 (ASP), 244 (ASP), 261 (ASP) and 266 (LYS). 
In vitro osteoblast assay 
ALP activities 
Alkaline phosphatase (ALP) activities were used to identify and 
quantify osteoblast (MC3T3-E1) differentiation, data was collected 
at day 1, 3, 5 and 7 after treatments of different concentrations of 
Etidronate and 2,3,3-TrisPP (0.01-2 mg/ml) in the present of ALP 
reaction solution (figure 8a & figure 8b). The results were obtained by 
measuring the absorbance (λabs 405 nm) of p-nitrophenol formation 
in osteoblast cultures. Figure 8 shows the ALP activities in osteoblasts 
after treatments of Etitronate (Figure 8a) and 2,3,3TrisPP (Figure 8b), 
high levels of ALP (4.0×10-7 – 6×10-7) were recorded in most cases when 
comparing to the control groups. Only a slight drop (<5%) was observed 
when cultures were exposed to 0.1 mg/ml of Etidronate and 0.01 mg/
ml of 2,3,3-TrisPP in day 3. A further decreased in the ALP level (~10 
%) was observed after 2,3,3-TrisPP treatments at concentrations of 0.01 
and 0.1 mg/ml in day 5 and 7. 
Mineralisation potentials 
Mineralisation of MC3T3-E1 cells following treatment were 
studied over a period of 5 weeks, calcium formation in cultures 
were determined by tagging Alizarin Red stain, visualised under 
light microscope (Figure 9 top) and subsequently analysed using 
colormetric assay (Figure 9 bottom). The top microscopic images show 
selective osteoblast mineralisation process in the present of Etidronate 
(Figure 9a) and 2,3,3-TrisPP (Figure 9b) at different concentrations 
(0.01-2 mg/ml) in week 5. † It is worth noting that 2,3,3-TrisPP at 
concentration 0.01 mg/ml exhibited optimum promotion in osteoblast 
mineralisation, as clear orange extracellular matrix nodules formation 
resulted from calcium deposits binding were observed. The highest 
calcium levels were measured at 1.3-1.5-fold changes (ca. control 
= 1) when MC3T3-E1 cells were treated with 0.01 and 0.1 g/ml of 
2,3,3-TrisPP for 5 weeks, hence 2,3,3-TrisPP at low concentrations 
significantly increased osteoblast mineralisation.   
Discussion 
Cytotoxic effects of 2,3,3-TrisPP in osteoclast-like cells 
Preliminary cytotoxic studies were performed using differentiated 
osteoclastic cell line derived from mouse leukaemic monocyte-
macrophages (RAW264.7). This particular derivative has been 
identified as a transfectable RANK-expressing cell line that activates 
nuclear factor kappa B (NF-kB), osteoclastic phenotype and bone 
resorption. In vitro results obtained from cell viabilities (Figure 5b), 
actin ring study (Figure 5d) and TRAP expression (Figure 5f) from 
osteoclast-like cells showed different levels of toxic effects induced 
by 2,3,3-TrisPP at various concentrations (0.01-2 mg/ml).† When 
comparing results obtained from Etidronate treatments (Figure 5a, 5c 
and 5e), a significant decline in osteoclastic activity was observed in all 
data collected upon treatments of 2,3,3-TrisPP at 0.5 mg/ml or above 
(Figure 5b, 5d and 5f). Fluorescent images (Figure 5d) obtained from 
actin study showed alteration in the cytoskeleton and some disruptions 
of the ruffled border suggested direct morphological changes in the 
osteoclast-like cells. Cell viabilities (Figure 6) of osteoclasts were 
determined by cell counting protocols, [50,51] lethal concentration 
(LC50) of 2,3,3-TrisPP calculated as 0.17, which showed over 7 times 
Figure 6. (a) Cell viability in osteoclast-like cells after 24 hours Etidronate and TrisPP treatments. (b) Lethal concentrations of Etidronate (LC50 1.25 mg/ml) and 2,3,3-TrisPP (LC50 0.172 
mg/ml) in osteoclst-like cells.
EST. free energy 
of binding 





Energy Interact. surface 
-4.73 kcal/mol -5.22 kcal/mol -0.43 kcal/mol -5.65 kcal/mol 504.899 
Table 1. Calculated binding energies from 2,3,3-TrisPP-hFPPS molecular docking 
simulations 
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Figure 7. (a) Molecular docking 2D model (partial image) demonstrates binding interactions between 2,3,3TrisPP and amino acids involve in the hFPPS cavity, green dash lines indicate 
hydrogen bonding formations with calculated bond lengths. (b) Hydrogen bonding plot shows potential satisfying hydrogen bonding formation from 2,3,3-TrisPP and amino acids sequence 
present in hFPPS protein. 
Figure 8a. APL activities were measured to quantify numbers of differentiated osteoblast cells under treatments of Etidronate.
Figure 8b. APL activities were measured to quantify numbers of differentiated osteoblast cells under treatments of 2,3,3-TrisPP
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Figure 9. Mineralisation potential of osteoblasts (top) after MC3T3-E1 cultures were exposed to different concentrations (0.01-2 mg/ml) of Etidronate (a) and 2,3,3-TrisPP (b) for week 
5. Orange nodules observed were due to calcium deposit and Alizarin Red binding.  Quantitative analysis (bottom) of calcium formation via osteoblast mineralisation upon Etidronate and 
2,3,3-TrisPP treatments after 5 week.
more cytotoxic effect to osteoclast-like cells than Etidronate (LC50 
= 1.25). Moreover, 2,3,3-TrisPP showed not only to exert cytotoxic 
effects in osteoclast-like cells, but it also appeared to inhibit their cell 
proliferation. Figure 6b shows stages of osteoclasts proliferation over 
a period of 7 days and clearly indicates inhibitory effects on osteoclast 
recruitment/adhesion and shortened their life span upon 2,3,3-TrisPP 
treatments at concentration as low as 0.01 mg/ml in day 3 and onwards. 
High binding affinity level calculated from human FPPS and 
2,3,3-TrisPP models 
Despite clinical BPs have been used as first line treatments for bone 
diseases in the last four decades, their molecular mechanisms of action 
have only become apparent in the last ten years [10,52]. There are two 
major pathways that have been generally recognised so far.11 It is known 
that non-nitrogen containing BPs inhibit osteoclast proliferation by 
interfering the ATP biosynthesis and leading to form a BP-metabolite 
analogue. An example of a BP-metabolite analogue formed by 
Etidronate is presented in figure 1 (structure on the right). Whereas 
N-BPs induce osteoclast apoptosis by selectively binding to enzyme 
farnesyl pyrophosphate synthase (FPPS) and subsequently prevent the 
prenylation steps in cholesterol synthesis via the mevalonate pathway 
(Figure 2) [10-12]. 
Our computational docking simulation results obtained from 
the human FPPS protein model (2f7m) support the above theory. 
For example, when a N-BP (i.e. Ibandronate) was used as a ligand 
model, high binding affinity with un-liganded hFPPS protein was 
calculated, whereas no binding interaction was found when ligand 
model was replaced by non-nitrogen BPs (i.e. Clodronate/ Etidronate). 
Interestingly, such theory did not apply to our non-nitrogen containing 
2,3,3-TrisPP when the same simulation method was applied. These are 
illustrated in 2D (Figure 7a) and 3D model (Figure 10) as 2,3,3-TrisPP 
fits into the hFPPS cavity perfectly and provides high level of docking 
interactions at minimal required binding energies (Table 1). 
The additional phosphoryl unit located at the C-atom adjacent to 
the bisphosphonate α-Carbon in the 2,3,3-TrisPP provided a ‘pendant-
effect’ (Figure 10b), which happens to have similar geometry to the 
highly potent N-BPs that is required to bind to FPPS enzyme. This is 
supported by data obtained from hydrogen bonding plot (Figure 7b, 
10b and 10c), the amino acid sequences (i.e. Lys200, Thr201, Gln240) 
that are satisfactory for potential hydrogen bonding formation match 
well with binding locations obtained from crystallography in-situ 
data produced by other N-BPs analogues (i.e. Zolendronate) [41]. 
This suggests nonnitrogen containing 2,3,3-TrisPP may undergo dual 
molecular actions to inhibit osteoclastic activities: (1) by manipulating 
ATP metabolite formation to give the proposed analogue as drawn in 
figure 11 (right); (2) by binding to FPPS to prevent the mevalonate 
biosynthesis as proposed in schematic figure 11 (left) 
Osteoblast differentiation and mineralisation 
Bone metabolism is a constant dynamic process where osteoclasts 
are responsible for bone resorption and osteoblasts for bone formation. 
Therefore, the balance of osteoclasts and osteoblasts levels is crucial for 
bone repairing and regulating bone mineral density. Mineralisation 
process is an essential step for bone development and regeneration, it is 
a process when osteocytes are produced and where the basic scaffolds 
of hydroxyapatite are being formed. Recent studies have shown that 
some BPs are able to preserve osteoblast and osteocyte viability, [53] it 
is interesting that our 2,3,3-TrisPP also appear to have such capability 
toward the osteoblasts (MC3T3-E1) we used in this study. MC3T3-E1, 
a pre-cultured mouse cell line, is commonly used as a model for 
studying osteoblasts differentiation, because it has behaviour similar 
to primary calvarial osteoblasts. This cell line gives observable levels of 
osteoblast differentiation when it is treated with the growth osteogenic 
medium, it also forms a well mineralised extracellular matrix when it 
reacted with Ca+ ions [54]. 
In our study, high levels of ALP activities (Figure 8b) in the 
osteoblastic culture were measured upon treatments with 2,3,3-TrisPP 
at all concentrations (0.01-2 mg/ml). This suggested cell had undergone 
a progressive osteoblast differentiations and that the process was not 
interrupted, but encouraged by the present of 2,3,3-TrisPP. Moreover, 
interesting data collected from the mineralisation potential study 
showing clear orange extracellular matrix nodules were formed and 
visualised (top right image in Figure9), this had also brought to our 
attention. The formation of intensive orange nodules (as illustrated 
in top figure 9b) were due to a collective binding of calcium deposits 
after labelling cells with Alizarin Red S stain in osteoblastic MC3T3-E1 
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Figure 10. (a) 3D docking image in full showing the entire geometry of single ligand 2,3,3-TrisPP slotted into the centre cavity of the hFPPS macro-protein. (b) A zoomed in image showing 
hydrogen interaction (O••H••O)  between the oxygen atom located in the extra phosphoryl unit in 2,3,3-TrisPP with amidic oxygen in Thr201. (c) A zoomed in image shows hydrogen 
interaction (O••H••N) involving an oxygen atom from the germinal bisphosphonate unit and a nitrogen atom from amide unit in Gln240. 
Figure 11. Proposed dual mechanistic actions of novel 2,3,3-TrisPP in osteoclasts involving manipulation of ATP biosynthesis (right) and inhibitory effect in FPPS enzyme in the mevalonate 
pathway (left). 
cultures, which were incubated in 2,3,3-TrisPP (0.01 mg/ml) for 5 
weeks. In summary, 2,3,3-TrisPP at low concentrations (0.01-0.1 mg/
ml) showed to preserve cell proliferation, promote cell differentiation 
and facilitate mineralisation in osteoblasts, these evident suggested that 
novel 2,3,3-TrisPP can be used potentially to aid processes involving 
bone deposition and regeneration. 
Conclusions 
In general, we found the molecular chemistry of this 2,3,3-TrisPP 
and their derivatives are very interesting. The convenient syntheses 
of these compounds are worth highlighting, together with the 
chemical structures of these highly bulky systems, where multiple 
phosphoryl units are fitted in a close proximity would also an interest 
of spectroscopy chemists. Although not published, we also learnt 
from our extended study that these compounds is capable of forming 
organometallic complex with metals. 
In our biological study, 2,3,3-TrisPP was found to exhibit inhibitory 
effect in osteoclastic cells over 7 times higher than the reference BP 
(Etidronate). Computational docking simulation suggested that 
2,3,3-TrisPP may undergo more than one cellular pathways to inhibit 
the functions of osteoclast-like cells as proposed in schematic figure 11. 
We found that 2,3,3-TrisPP not only inhibited osteoclast activity, but 
it also promoted osteoblast differentiation and the latter mineralisation 
process. 
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Overall, we found the molecular nature of these trisphosphonate 
systems are surprisingly diverse with respect to its chemistry and 
biology. The observed inhibitory effects in osteoclastic cells and the 
facilitation in osteoblastic mineralization exerted by 2,3,3-TrisPP 
treatments imply its potential applications in bone therapy, as it may 
help reducing bone resorption while promoting bone deposition. 
Therefore, it is worth investigate these compounds further to explore 
their biological and medical functions. 
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